Search Results for: 116

-Completed acquisition of VCN Biosciences, expanding pipeline into oncology- -VCN-01 received Orphan Drug Designation for retinoblastoma from the U.S. FDA- -As of December 31, 2021, Synthetic Biologics reports $67.3 million in cash, which is expected to provide runway through the end of 2023- -Conference call and webcast to be held today at 4:30 p.m. ET- […]

Initiated a Phase 1 Multiple Ascending Dose Clinical Trial of SYN-020 in Healthy Adult Volunteers; Topline Data Readout Expected in Q2 2022 Enrollment Remains Ongoing in Phase 1b/2a Clinical Trial of SYN-004 in Allogeneic HCT Recipients Reports $72.1 Million of Cash on Hand to Fund Clinical Programs Through Key Milestones Beyond 2022 ROCKVILLE, Md., Nov.

— Announced Washington University Has Begun Screening Patients for Enrollment in Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients — — Reports $72.6M of Cash on Hand to Fund Clinical Programs and Extend Operations into 2023 — — Conference Call Today at 4:30 p.m. (ET) — ROCKVILLE, Md., March 4,

— Conference Call Scheduled for Tuesday, November 10, 2020 at 4:30 p.m. ET — ROCKVILLE, Md., Nov. 3, 2020 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need, announced today that the

— Enrollment is Ongoing in Phase 2b Investigator-Sponsored Clinical Study of SYN-010, for the Treatment of IBS-C; Topline Data Readout Anticipated in 2H 2019 — — Conference Call Wednesday, February 27, 2019, at 4:30 p.m. (EST) — ROCKVILLE, Md., Feb. 27, 2019 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE American: SYN), a clinical-stage company developing therapeutics that preserve

Clinical Study of SYN-010, for the Treatment of IBS-C ROCKVILLE, Md., Jan. 3, 2019 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics designed to preserve the microbiome to protect and restore the health of patients, today announced that the first two patients have been enrolled in SYN-010’s Phase 2b investigator-sponsored clinical

— Announced Agreement with Cedars-Sinai Medical Center to Co-fund a Phase 2b Investigator-Sponsored Clinical Study of SYN-010, for the Treatment of IBS-C — — Strengthened Balance Sheet in Support of Microbiome-Focused Clinical Development Programs — — Conference Call Today, November 8, 2018, at 4:30 p.m. (EST) — ROCKVILLE, Md., Nov. 8, 2018 /PRNewswire/ — Synthetic Biologics,

— SYN-004 End of Phase 2 Meeting with U.S. Food & Drug Administration on Track for Third Quarter of 2018 — — Conference Call Today, August 8, 2018, at 4:30 p.m. (EDT) — ROCKVILLE, Md., Aug. 8, 2018 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics that preserve the microbiome

— Preliminary Agreement Reached with FDA on Proposed Phase 3 Clinical Trial Synopsis for SYN-004 (ribaxamase) — — Conference Call Today, May 8, 2018, at 4:30 p.m. (EDT) — ROCKVILLE, Md., May 8, 2018 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics that preserve the microbiome to protect and restore